Tags: Ebola Outbreak | Ebola | vaccines | trials | GSK

GSK Ebola Vaccine Fast-Tracked for Human Trials

By    |   Wednesday, 26 November 2014 08:37 PM

Preliminary results in human volunteers are promising from U.S. trials of one of the leading Ebola vaccine candidates.

The vaccine from British manufacturer GlaxoSmithKline — developed with the National Institutes of Health — is one of three being sped into trials in west Africa. The aim is to test the vaccine in January on healthcare workers, burial teams and others at high risk of infection, the Guardian reports.

The results were published Wednesday in the New England Journal of Medicine, showing that vaccinations of the first healthy volunteers in the United States show no ill effects; all 20 developed antibodies to the virus.

"We are very encouraged by these positive first trial results showing this type of vaccine has an acceptable safety profile and can produce an immune response against Ebola in humans," Dr. Moncef Slaoui, chairman of global vaccines at GSK, told The Guardian.

The World Health Organization reports that as of Sunday, there have been 15,935 reported cases and 5,689 deaths.

© 2020 Newsmax. All rights reserved.


   
1Like our page
2Share
US
Preliminary results in human volunteers are promising from U.S. trials of one of the leading Ebola vaccine candidates.
Ebola, vaccines, trials, GSK
162
2014-37-26
Wednesday, 26 November 2014 08:37 PM
Newsmax Media, Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved